Rituximab or rituximab plus chlorambucil for translocation (11;18)-negative gastric mucosa-associated lymphoid tissue lymphoma: a monocentric non-randomized observational study

References

• Nakamura S, Sugiyama T, Matsumoto T, JAPAN GAST Study Group, et al. Long-term clinical outcome of gastric MALT lymphoma after eradication of Helicobacter pylori: a multicentre cohort follow-up study of 420 patients in Japan. Gut 2012;61(4):507–513.
   PubMed Web of Science ®Google Scholar
• Zucca E, Arcaini L, Buske C, ESMO Guidelines Committee. Electronic address: [email protected], et al. Marginal zone lymphomas: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020;31(1):17–29.
   PubMed Web of Science ®Google Scholar
• Rodríguez-Sevilla JJ, Salar A. Recent advances in the genetic of MALT lymphomas. Cancers 2021;14(1):176.
   PubMedGoogle Scholar
• Lévy M, Copie-Bergman C, Gameiro C, et al. Prognostic value of translocation t(11;18) in tumoral response of low-grade gastric lymphoma of mucosa-associated lymphoid tissue type to oral chemotherapy. J Clin Oncol. 2005;23(22):5061–5066.
   PubMed Web of Science ®Google Scholar
• Amiot A, Lévy M, Copie-Bergman C, et al. Rituximab, alkylating agents or combination therapy for gastric mucosa-associated lymphoid tissue lymphoma: a monocentric non-randomised observational study. Aliment Pharmacol Ther. 2014;39(6):619–628.
   PubMedGoogle Scholar
• Liu H, Ye H, Ruskone-Fourmestraux A, et al. T(11;18) is a marker for all stage gastric MALT lymphomas that will not respond to H. pylori eradication. Gastroenterology 2002;122(5):1286–1294.
   PubMed Web of Science ®Google Scholar
• Ye H, Liu H, Attygalle A, et al. Variable frequencies of t(11;18)(q21;q21) in MALT lymphomas of different sites: significant association with CagA strains of H. pylori in gastric MALT lymphoma. Blood 2003;102(3):1012–1018.
   PubMed Web of Science ®Google Scholar
• Zucca E, Conconi A, Martinelli G, et al. Final results of the IELSG-19 randomized trial of mucosa-associated lymphoid tissue lymphoma: improved event-free and progression-free survival with rituximab plus chlorambucil versus either chlorambucil or rituximab monotherapy. J Clin Oncol. 2017;35(17):1905–1912.
   PubMed Web of Science ®Google Scholar
• Rotkopf H, Lévy M, Copie-Bergman C, et al. Effectiveness and safety of subcutaneous rituximab for patients with gastric MALT lymphoma: a case-control comparison with intravenous rituximab. Clin Lymphoma Myeloma Leuk. 2021;21(1):e32–e38.
   PubMedGoogle Scholar
• Swerdlow SH, Swerdlow SH, Campo E, et al. Classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Geneva: World Health Organization (WHO); 2017 [accessed 2020 Aug 31]. Available from: https://publications.iarc.fr/Book-And-Report-Series/Who-Classification-Of-Tumours/WHO-Classification-Of-Tumours-Of-Haematopoietic-And-Lymphoid-Tissues-2017.
   Google Scholar
• Lévy M, Copie-Bergman C, Molinier-Frenkel V, et al. Treatment of t(11;18)-positive gastric mucosa-associated lymphoid tissue lymphoma with rituximab and chlorambucil: clinical, histological, and molecular follow-up. Leuk Lymphoma. 2010;51(2):284–290.
   PubMed Web of Science ®Google Scholar
• Musshoff K. Clinical staging classification of non-Hodgkin’s lymphomas (author’s transl). Strahlentherapie 1977;153(4):218–221.
   PubMedGoogle Scholar
• Thieblemont C, Cascione L, Conconi A, et al. A MALT lymphoma prognostic index. Blood 2017;130(12):1409–1417.
   PubMed Web of Science ®Google Scholar
• Conconi A, Martinelli G, Thiéblemont C, et al. Clinical activity of rituximab in extranodal marginal zone B-cell lymphoma of MALT type. Blood 2003;102(8):2741–2745.
   PubMed Web of Science ®Google Scholar
• Martinelli G, Laszlo D, Ferreri AJM, et al. Clinical activity of rituximab in gastric marginal zone non-Hodgkin’s lymphoma resistant to or not eligible for anti-Helicobacter pylori therapy. J Clin Oncol. 2005;23(9):1979–1983.
   PubMed Web of Science ®Google Scholar
• Lévy M, Copie-Bergman C, Amiot A, et al. Rituximab and chlorambucil versus rituximab alone in gastric mucosa-associated lymphoid tissue lymphoma according to t(11;18) status: a monocentric non-randomized observational study. Leuk Lymphoma. 2013;54(5):940–944.
   PubMed Web of Science ®Google Scholar
• Copie-Bergman C, Wotherspoon AC, Capella C, et al. Gela histological scoring system for post-treatment biopsies of patients with gastric MALT lymphoma is feasible and reliable in routine practice. Br J Haematol. 2013;160(1):47–52.
   PubMed Web of Science ®Google Scholar
• Cheson BD, Pfistner B, Juweid ME, International Harmonization Project on Lymphoma, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25(5):579–586.
   PubMed Web of Science ®Google Scholar
• Copie-Bergman C, Wotherspoon A. MALT lymphoma pathology, initial diagnosis, and posttreatment evaluation. In: Cavalli F, Stein H, Zucca E, editors. Extranodal lymphomas pathology and management. London, UK: Informa Healthcare; 2008. p. 114–123.
   Google Scholar
• Common Terminology Criteria for Adverse Events (CTCAE) | Protocol Development | CTEP. [accessed 2022 Jan 6]. Available from: https://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm.
   Google Scholar
• Zucca E, Conconi A, Laszlo D, et al. Addition of rituximab to chlorambucil produces superior event-free survival in the treatment of patients with extranodal marginal-zone B-cell lymphoma: 5-year analysis of the IELSG-19 randomized study. J Clin Oncol. 2013;31(5):565–572.
   PubMed Web of Science ®Google Scholar
• Sagaert X, Van Cutsem E, De Hertogh G, et al. Gastric MALT lymphoma: a model of chronic inflammation-induced tumor development. Nat Rev Gastroenterol Hepatol. 2010;7(6):336–346.
   PubMed Web of Science ®Google Scholar
• Rentien AL, Lévy M, Copie-Bergman C, et al. Long-term course of precancerous lesions arising in patients with gastric MALT lymphoma. Dig Liver Dis. 2018;50(2):181–188.
   PubMedGoogle Scholar
• Wündisch T, Dieckhoff P, Greene B, et al. Second cancers and residual disease in patients treated for gastric mucosa-associated lymphoid tissue lymphoma by Helicobacter pylori eradication and followed for 10 years. Gastroenterology 2012;143(4):936–942. quiz e13–14.
   PubMedGoogle Scholar
• Copie-Bergman C, Locher C, Levy M, et al. Metachronous gastric MALT lymphoma and early gastric cancer: is residual lymphoma a risk factor for the development of gastric carcinoma? Ann Oncol. 2005;16(8):1232–1236.
   PubMedGoogle Scholar
• Conconi A, Thieblemont C, Cascione L, et al. Early progression of disease predicts shorter survival in MALT lymphoma patients receiving systemic treatment. Haematologica 2020;105(11):2592–2597.
   PubMed Web of Science ®Google Scholar